NASDAQ:EDIT Editas Medicine Q2 2026 Earnings Results & Report $2.90 +0.06 (+2.11%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.89 -0.01 (-0.34%) As of 10/9/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Editas Medicine beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 5, 2026. The company reported EPS of -$0.15 versus the -$0.2705 consensus estimate, while revenue of $11.89 million topped the $2.85 million estimate by $9.04 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Editas Medicine EPS ResultsActual EPS-$0.15Consensus EPS -$0.2705Beat/MissBeat by +$0.1205One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEditas Medicine Revenue ResultsActual Revenue$11.89 millionExpected Revenue$2.85 millionBeat/MissBeat by +$9.04 millionYoY Revenue GrowthN/AUpcoming EarningsEditas Medicine's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Editas Medicine Q2 2026 Earnings FAQ Did Editas Medicine beat earnings estimates for Q2 2026? Editas Medicine (NASDAQ:EDIT) reported earnings of -$0.15 per share for Q2 2026, beating the consensus estimate of -$0.2705. The report was announced on Wednesday, August 5, 2026. What was Editas Medicine's revenue for Q2 2026? Editas Medicine reported revenue of $11.89 million for Q2 2026, against a consensus estimate of $2.85 million. When is Editas Medicine's next earnings date? Editas Medicine's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Editas Medicine on the company's earnings history page. Editas Medicine Earnings HeadlinesEDIT Set to Begin First-in-Human Study in HypercholesterolemiaOctober 9 at 3:08 PM | finance.yahoo.comEditas Medicine Receives Approval To Initiate Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In AustraliaOctober 9 at 10:04 AM | marketscreener.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 10 at 1:00 AM | Altimetry (Ad)Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price TargetOctober 8 at 12:09 AM | finance.yahoo.comWells Fargo upgrades Editas Medicine to overweight from equal-weightOctober 8 at 12:09 AM | msn.comEditas Advances Gene-Editing Program Into First Human Study For High CholesterolOctober 8 at 7:08 PM | rttnews.comSee More Editas Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email. Email Address About Editas MedicineEditas Medicine (NASDAQ:EDIT) is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The company’s research programs are designed to modify or correct disease-associated genes in patients’ cells, with the goal of developing potentially durable treatments. Its lead investigational program is reni-cel, formerly known as EDIT-301, an ex vivo CRISPR gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. Editas has also pursued additional programs involving both ex vivo and in vivo gene editing, including potential treatments for genetic diseases affecting the blood and eyes. These therapies remain investigational and are subject to clinical and regulatory evaluation. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas Medicine conducts research and clinical development activities intended to serve patients internationally. The company was established by researchers and biotechnology industry professionals, including prominent scientists associated with the development of CRISPR gene-editing technology. Its business is centered on advancing proprietary gene-editing platforms and translating them into medicines for serious diseases with limited treatment options.View Editas Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
